Flag of the European Union EU Clinical Trials Register Help

Clinical trials for E glass

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    15 result(s) found for: E glass. Displaying page 1 of 1.
    EudraCT Number: 2004-000811-24 Sponsor Protocol Number: 308260 Start Date*: 2004-11-19
    Sponsor Name:Schering AG
    Full Title: Multicenter, double-blind, randomized, pleacebo-controlled study to evaluate the oral low-dose estradiol preparations SH T 04170 E (100 µg estradiol) and SH T 04170 F (190 µg estradiol) in postmeno...
    Medical condition: postmenopausal women with high risk for osteoporosis
    Disease: Version SOC Term Classification Code Term Level
    7.0 10050213 LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2004-004095-37 Sponsor Protocol Number: CQAB149A2222 Start Date*: 2005-02-25
    Sponsor Name:Novartis Pharma Services
    Full Title: An exploratory, multi-center, randomized, open-label, single dose, crossover study to assess the safety and tolerability of 200µg of QAB149, delivered via a MDDPI, with or without the co-administra...
    Medical condition: 1) Stable persistent asthma 2) COPD
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) BE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-002119-23 Sponsor Protocol Number: IEO1253 Start Date*: 2020-11-16
    Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA
    Full Title: COVitaminD Trial: prevention of complications from COVID-19 in cancer patients under active treatment
    Medical condition: Oncological patients in active oncological treatment diagnosed with Covid-19
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10010029 Colorectal cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-001597-30 Sponsor Protocol Number: MRx-4DP0004-II-001 Start Date*: 2020-05-29
    Sponsor Name:4D pharma plc
    Full Title: A pilot, multiple dose study to evaluate the efficacy and safety of MRx-4DP0004 in hospitalised patients with symptoms of COVID-19 (SARS-CoV-2 infection)
    Medical condition: Symptoms of Covid-19 infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10061986 SARS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2020-001325-31 Sponsor Protocol Number: NL73551.091.20 Start Date*: 2020-05-20
    Sponsor Name:Radboud University Medical Center
    Full Title: [68Ga]Ga-DOTA-(RGD)2 PET/CT imaging of activated endothelium in lung parenchyma of COVID-19 patients.
    Medical condition: Maximum 10 patients from the Infectious Diseases ward with proven COVID-19 infection and pulmonary abnormalities on contrast-enhanced CT undergo static PET scans after injection of 70 μg (200 MBq) ...
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004855 10047468 Viral lower respiratory tract infections HLT
    20.1 100000004855 10047483 Viral upper respiratory tract infections HLT
    21.1 100000004855 10038701 Respiratory insufficiency LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2020-001473-79 Sponsor Protocol Number: ESR-20-20653 Start Date*: 2020-05-07
    Sponsor Name:Saint Luke’s Hospital of Kansas City, Kansas City, Missouri, USA
    Full Title: An International, Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Dapagliflozin in Respiratory Failure in Patients with COVID-19
    Medical condition: Respiratory Failure in patients with COVID-19
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2013-003689-15 Sponsor Protocol Number: StopEAA Start Date*: 2015-01-21
    Sponsor Name:Klinikum der Universität München
    Full Title: Stop exogenous allergic alveolitis (EAA) in childhood: healthy into adulthood – a randomized, double-blind, placebo-controlled, parallel-group study to evaluate prednisolone treatment and course of...
    Medical condition: exogenous allergic alveolitis (EAA)
    Disease: Version SOC Term Classification Code Term Level
    17.1 10038738 - Respiratory, thoracic and mediastinal disorders 10001890 Alveolitis allergic PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-004405-34 Sponsor Protocol Number: GS-US-231-0101 Start Date*: 2010-09-13
    Sponsor Name:Gilead Sciences Incorporated
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group, Event-Driven Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Early Idiopathic Pulmon...
    Medical condition: Idiopathic pulmonary fibrosis (IPF)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10021240 Idiopathic pulmonary fibrosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) IE (Prematurely Ended) DE (Prematurely Ended) AT (Prematurely Ended) BE (Completed) ES (Prematurely Ended) NL (Completed) FR (Completed) GB (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-001612-25 Sponsor Protocol Number: REP0122 Start Date*: 2022-10-12
    Sponsor Name:DOMPé FARMACEUTICI S.P.A.
    Full Title: Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and safety of reparixin as add-on therapy to standard of care in adult patients with ...
    Medical condition: Acute Respiratory Distress Syndrome
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10001052 Acute respiratory distress syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-001281-86 Sponsor Protocol Number: CNTO888PUL2001 Start Date*: 2009-01-14
    Sponsor Name:Centocor B.V.
    Full Title: A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 888 Administered Intravenously in ...
    Medical condition: Idiopathic pulmonary fibrosis (IPF)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10021240 Idiopathic pulmonary fibrosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-000509-31 Sponsor Protocol Number: 206-OC-202 Start Date*: 2007-10-10
    Sponsor Name:Biogen Idec Ltd
    Full Title: Estudio en fase 1/2, abierto, adaptativo, aleatorio de doxorrubicina liposómica con o sin M200 (volociximab) para el tratamiento de pacientes con cáncer de ovario epitelial avanzado o cáncer perito...
    Medical condition: Cáncer de ovario epitelial avanzado o cáncer peritoneal primario Advanced epithelial ovarian cancer or primary peritoneal cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed) BE (Completed) SE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-023047-15 Sponsor Protocol Number: CC-4047-SSC-001 Start Date*: 2012-03-15
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 2 Proof-of-Concept, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC...
    Medical condition: systemic sclerosis associated with interstitial lung disease
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004855 10025109 Lung involvement in systemic sclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Completed) IT (Prematurely Ended) ES (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2010-018414-69 Sponsor Protocol Number: 4305-029 Start Date*: 2010-05-23
    Sponsor Name:Merck & Co., Inc.
    Full Title: "Estudio de fase III, multicéntrico, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos para evaluar la seguridad y la eficacia de MK-4305 en pacientes con insomnio primario -Es...
    Medical condition: Insomnio Primario /Primary Insomnia
    Disease: Version SOC Term Classification Code Term Level
    11 10036701 Insomnio primario LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) GB (Completed) FI (Completed) SE (Completed) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-011169-98 Sponsor Protocol Number: GS-US-300-0128 Start Date*: 2009-11-03
    Sponsor Name:Gilead Sciences, Inc
    Full Title: ARTEMIS-PH: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Idiopathic Pulmonary Fibr...
    Medical condition: Pulmonary Hypertension associated with Idiopathic Pulmonary Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    12.0 10021240 Idiopathic pulmonary fibrosis LLT
    12.0 10037400 Pulmonary hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended) GB (Prematurely Ended) IT (Prematurely Ended) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-005017-23 Sponsor Protocol Number: FM-14-B02 Start Date*: 2016-01-26
    Sponsor Name:Fondazione Michelangelo - Avanzamento dello studio e cura dei tumori
    Full Title: Neo-Adjuvant study with the PDL1-directed antibody in Triple Negative, Early High-Risk and Locally Advanced Breast Cancer undergoing treatment with nab-paclitaxel and carboplatin
    Medical condition: Women with a diagnosis of invasive unilateral, early high-risk and locally advanced or inflammatory, triple negative (HER2-negative and ER-negative and PgRnegative) breast cancer of high proliferat...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006200 Breast cancer stage II PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006196 Breast cancer NOS stage III LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006195 Breast cancer NOS stage II LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006201 Breast cancer stage III PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10021975 Inflammatory breast cancer stage III LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) AT (Completed) ES (Completed) IE (Completed) IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 19 13:16:30 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA